Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.

Item

http://www.wikidata.org/entity/Q48030231

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Cost-effectiveness analysis of ...... not responding to interferon.

@en

Cost-effectiveness analysis of ...... not responding to interferon.

@nl

type

Item

label

Cost-effectiveness analysis of ...... not responding to interferon.

@en

Cost-effectiveness analysis of ...... not responding to interferon.

@nl

prefLabel

Cost-effectiveness analysis of ...... not responding to interferon.

@en

Cost-effectiveness analysis of ...... not responding to interferon.

@nl

P1476

Cost-effectiveness analysis of ...... not responding to interferon.

@en

P2093

Buti M

http://www.w3.org/2001/XMLSchema#string

Cabasés JM

http://www.w3.org/2001/XMLSchema#string

Guillén-Grima F

http://www.w3.org/2001/XMLSchema#string

Mar J

http://www.w3.org/2001/XMLSchema#string

San Miguel R

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.

Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis.

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

P304

765-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2036.2003.01494.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10851412

http://www.w3.org/2001/XMLSchema#string

P698

12641498

http://www.w3.org/2001/XMLSchema#string